APRE — Aprea Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.52m
- -$33.99m
- $0.29m
Brief: Aprea Therapeutics Announces Submission of IND Application for APR-1051
Brief: Aprea Therapeutics Says Entered Into An At Market Offering Agreement With HC Wainwright & Co
Brief: Aprea Therapeutics Files For Mixed Shelf Of Up To $150 Million
Aprea Therapeutics Inc expected to post a loss of $1.16 a share - Earnings Preview
Brief: Aprea Unveils Initial Clinical Data On ATRi, ATRN-119, And Pre-Clinical Data On WEE1i, ATRN-1051
Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aprea Therapeutics Q2 EPS USD -0.87
Aprea Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
Brief: Aprea Therapeutics Recieves Nasdaq Approved Application To Transfer Listing
Brief: Aprea Therapeutics Reports First Quarter 2023 Financial Results
Aprea Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Aprea Therapeutics Inc expected to post a loss of $1.50 a share - Earnings Preview
Brief: Aprea Therapeutics Inc Board Increased Size Of Board From Eight To Nine Directors
Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aprea Therapeutics Inc Reports Quarterly Net Loss Of $2.4 Million Or $0.92 Per Basic Share
Aprea Therapeutics Inc expected to post a loss of $3.08 a share - Earnings Preview
Brief: Aprea Therapeutics Currently Maintains About $1.5 Million In Cash Deposits At SVB
Aprea Therapeutics Inc expected to post a loss of $2.60 a share - Earnings Preview
Brief: Aprea Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement